SEC Form 4 · accession 0001493152-26-039286
Calidi Biotherapeutics, Inc. · CLDI
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Santidrian Antonio Fernandez
Officer — Chief Scientific Officer
Period of report
Aug 17, 2026
Accepted (ET)
Aug 19, 2026 · 7:00 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001855485
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Options (right to buy)F1,F2 | $1.36 | Aug 17, 2026 | A | 16,000 | A | Aug 17, 2026 | Aug 17, 2036 | Common stock | 16,000 | 16,000 | D |
Explanation of responses
- F1Pursuant to the Issuer's 2023 Equity Incentive Plan (the "2023 Plan"), on August 17, 2026 (the "Grant Date"), the Reporting Person was granted 16,000 incentive stock options (the "Options") at an exercise price of $1.36, which is equal to the closing price of the Issuer's common stock on the Grant Date. 25% of the options will vest upon the one (1) year anniversary of 08/17/2026, and the remaining 75% of the options will vest in 1/36th installments on a monthly basis, subject to the Reporting Person's continued service to the Issuer. The Options were granted in a transaction exempt under Rule 16b-3 to the Reporting Person.
- F2Does not include the incentive stock options previously granted to the Reporting Person.
Remarks
Exhibit 24 - Power of Attorney